Talquetamab Bridging Strategy Appears Feasible in R/R Multiple Myeloma
Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.
Previous Post
STAT+: Was the reaction to Viking’s oral data overblown?
Next Post
Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago